このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Senhwa Biosciences マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jin-Ding Huang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	7yrs

経営陣の近況

Recent updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

Jan 19

CEO（最高経営責任者

Jin-Ding Huang

2.4yrs

在職期間

Dr. Jin-Ding Huang, PhD, serves as Director since March 1, 2022 and Chief Executive Officer at Senhwa Biosciences, Inc. since 2022 and serves as its Chief Scientific Officer since 2022 until 2022 and as it...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sarah Chang	Vice President & CFO	10.3yrs	NT$8.76m	データなし
Jin-Ding Huang	CEO & Director	2.4yrs	データなし	データなし
Joanne Lo	Acting Chief Operating Officer & Business Development Director	1.3yrs	データなし	データなし

2.4yrs

平均在職期間

経験豊富な経営陣: 6492の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jin-Ding Huang	CEO & Director	2.3yrs	データなし	データなし
Ting-Wu Hu	Chairman	11.6yrs	データなし	データなし
Chia-Hung Lee	Supervisor	9.3yrs	データなし	データなし
Jo Shen	Director	1.4yrs	データなし	データなし
Chi-Hai Lin	Supervisor	8yrs	データなし	データなし
Jien-Fu Chen	Director	7yrs	データなし	データなし
Yeu-Chuyr Chang	Independent Director	9.3yrs	NT$160.00k	データなし
Eric Hu	Supervisor	7yrs	データなし	データなし
Yung-Lin Ma	Independent Director	4yrs	NT$80.00k	データなし
Tong-Young Lee	Independent Director	4yrs	NT$80.00k	データなし

7.0yrs

平均在職期間

経験豊富なボード: 6492の取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

Senhwa Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023)

Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022)

Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19

Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection

Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19

New minor risk - Share price stability

Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021)

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NT$143

Less than half of directors are independent

Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations

Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2)

Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020)

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment

First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020)

Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019)

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

New 90-day low: NT$162

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

New 90-day low: NT$172

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Earnings beat expectations

Third quarter 2020 earnings released: NT$1.52 loss per share

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19

New 90-day high - NT$181

First half earnings released

New 90-day high - NT$180

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /24